BAY 81-8973, a full-length recombinant factor VIII for the treatment of hemophilia A: product review

DOI: 10.1177/2040620718777903

Keywords: BAY 81-8973, hemophilia A, Kovaltry, pharmacokinetics, prophylaxis, recombinant factor VIII

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text